RedHill Biopharma (RDHL) Non-Current Deffered Revenue (2018 - 2023)

RedHill Biopharma (RDHL) has 6 years of Non-Current Deffered Revenue data on file, last reported at $540000.0 in Q4 2023.

• On a quarterly basis, Non-Current Deffered Revenue fell 28.0% year-over-year to $540000.0 in Q4 2023; TTM through Dec 2023 was $540000.0, a 28.0% decrease from a year earlier, with the FY2023 full-year figure at $540000.0, down 28.0% from the prior year.
• Non-Current Deffered Revenue for Q4 2023 stood at $540000.0, down from $750000.0 in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for RDHL reached as high as $750000.0 in Q4 2020 and fell as low as $500000.0 in Q4 2019.
• Historically, Non-Current Deffered Revenue has averaged $658000.0 across 5 years, with a median of $750000.0 in 2020.
• Across the five-year window, Non-Current Deffered Revenue jumped 50.0% in 2020 and slipped 28.0% in 2023, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $500000.0 in 2019, then soared by 50.0% to $750000.0 in 2020, then changed by 0.0% to $750000.0 in 2021, then changed by 0.0% to $750000.0 in 2022, then declined by 28.0% to $540000.0 in 2023.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $540000.0 in Q4 2023, $750000.0 in Q4 2022, and $750000.0 in Q4 2021.